In a Spanish cohort of 185 treatment-naïve patients, 12% of advanced lung adenocarcinoma cell-free DeoxyriboNucleic Acid (cfDNA) samples analyzed with Guardant360 harbored ARID1A mutations (61% pathogenic/likely pathogenic) [4]. Here, ARID1A is linked to lung adenocarcinoma.